Ginkgo Bioworks Acquires Assets from Bitome

Ginkgo Bioworks Acquires Zymergen

July 25, 2022

Biotechnology

Ginkgo Bioworks (NYSE: DNA) will acquire Zymergen in an all‑stock transaction valuing Zymergen at about $300 million; Zymergen stockholders will receive 0.9179 Ginkgo shares per Zymergen share and will own ~5.25% of the combined company. The acquisition is intended to integrate Zymergen's automation, software, and data‑science capabilities and biological assets into Ginkgo's horizontal cell‑programming platform to expand capacity, capabilities, and efficiency across multiple end markets.

Ginkgo Bioworks Acquires Patch Biosciences

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Patch Biosciences, a startup that built an AI platform for sequence design to advance genetic medicines. The acquisition will integrate Patch's machine‑learning models and validated assays into Ginkgo's platform to expand its gene therapy, cell therapy and RNA therapeutics capabilities for biopharma customers.

Ginkgo Bioworks Acquires Novogy's Microbial Engineering Platform

December 16, 2020

Biotechnology

Ginkgo Bioworks acquired the main assets of Novogy, Inc., absorbing Novogy's strain assets, IP portfolio, codebase and most of its technical team. The acquisition brings Novogy's expertise in lipid-producing oleaginous yeasts (notably Yarrowia lipolytica) into Ginkgo's cell‑programming platform to accelerate development of bio-based oils, chemicals and materials.

Ginkgo Bioworks Acquires Proof Diagnostics

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.

Ginkgo Bioworks Acquires Project Beacon COVID-19 LLC

January 19, 2022

Healthcare Services

Ginkgo Bioworks has acquired the assets and operations of Project Beacon COVID-19 LLC, a Boston-based social benefit organization that provided accessible COVID-19 testing across Massachusetts. The acquisition brings Project Beacon's partner relationships, digital platform, and personnel into Ginkgo’s Concentric by Ginkgo public health and biosecurity offering to expand COVID-19 monitoring and testing capabilities.

Parse Biosciences Acquires Biomage

January 16, 2024

Software

Parse Biosciences has acquired data analysis software company Biomage, integrating Biomage's cloud-based single-cell RNA sequencing analysis platform into Parse's product portfolio. The deal will give Parse customers access to faster, intuitive single-cell data analysis (Biomage's Cellenics/Cellscope), pairing Parse's Evercode combinatorial barcoding technology with Biomage's analysis tools to reduce analysis time and expand capabilities.